Druggability & Clinical Context
Druggability
Low
Score: 0.40
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
6
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: SRPK1 represents a promising druggable target for neurodegeneration due to its critical role in regulating alternative splicing of tau and other neurologically relevant proteins, with SPHINX31 demonstrating preclinical potential to modulate aberrant splicing mechanisms. The availability of high-resolution structural data (including PDB entries and AlphaFold predictions) and the kinase classification suggest tractable opportunities for developing selective small molecule inhibitors that could interrupt pathogenic protein misprocessing in neurodegenerative conditions.
Mechanism: SRPK1 inhibitors block phosphorylation of serine/arginine-rich splicing factors, modulating alternative splicing patterns implicated in neurodegeneration and cancer. By preventing aberrant splicing, these inhibitors can restore normal protein isoform expression and reduce pathogenic tau accumulation.
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:SPHINX31 (preclinical) — Cancer research
Structural Data:PDB (6) ✓AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
SRPK1 selectivity against other SRSF kinases (CLK family) and broader kinome represents a key challenge; however, SRPK1's unique substrate specificity toward serine/arginine-rich proteins offers potential for selective targeting. Off-target effects on related splicing kinases could complicate therapeutic window and require isoform-selective inhibitor design.